Ingenza announces move to purpose-built facilities to expand fermentation and research capacity

October 14, 2024 – BioManufacturing – CDMO, Facilities, Ingenza, Scotland

1 October 2024 – Roslin, Scotland – Ingenza – a world-leading contract research, development and manufacturing organisation (CRDMO) and technology accelerator – is delighted to announce its plans to relocate to the Moubray Building at Edinburgh Technopole, part of Pioneer Group. Following a detailed strategic review, the company has embarked on the creation of a multi-million pound facility to help drive its ambitious growth plans. The purpose-built premises will more than double Ingenza’s current footprint to approximately 25,000 square feet, expanding its fermentation and research facilities.

Jaymin Amin, Chief Business Officer of Ingenza, explained: “The expansion is a landmark investment for Ingenza, enabling us to increase our fermentation scale to 100L, as well as expanding our research and development labs to support larger programmes. Our inGenius™ platform technology is redefining drug substance development and sustainable biotech manufacturing, and this exciting move will provide an independent, world-class facility to better serve customers worldwide, accelerating our business growth.”

John Mackenzie, Director (Scotland) at Pioneer, said: “We are delighted that Ingenza will be located with us at Edinburgh Technopole. As a UK and world leader in industrial biotechnology, Ingenza is a very welcome addition to Pioneer’s ecosystem. Importantly, the business is remaining in the Midlothian Science Zone, while expanding its lab and office operations and creating 50 new highly skilled jobs. Ingenza’s growth is hugely positive for our local life sciences cluster, being an exemplar of the Pioneer model of local economic development, partnership and impact that will accelerate scientific discovery.”

Ingenza anticipates moving into the new facility in Q2 of 2025.

For more information, visit www.ingenza.com

About Ingenza

Ingenza is changing the game in product development with its innovative inGenius platform. The platform leverages 12 alternative host systems, customised gene design (codABLE^®) and high throughput screening (visABLE^®) to develop and optimise bioprocesses for a range of products, from therapeutics to industrial enzymes and consumer goods. By combining DoE and tailored fermentations, the inGenius platform increases predictability to rapidly advance targets to clinical studies and commercialisation. As an engineering biology CRDMO and pipeline accelerator, Ingenza provides fast, efficient and cost-effective solutions to advance your novel targets.